Teva Adds Needed Latin American Puzzle Piece With Rimsa Buy
This article was originally published in The Pink Sheet Daily
The Israeli generic drug firm is positioning itself for long-term growth in the region through the acquisition of one of the top drug manufacturers in Mexico.
You may also be interested in...
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.